This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Aureo Co., Ltd.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Yasuhiro Nikawa: Innovator in Macrophage Phagocytosis
Introduction
Yasuhiro Nikawa is a notable inventor based in Kimitsu, Japan. He has made significant contributions to the field of immunology, particularly in the activation of macrophage phagocytosis. His innovative work has the potential to impact cancer treatment and enhance immune responses.
Latest Patents
Yasuhiro Nikawa holds a patent for a composition that activates macrophage phagocytosis and promotes cytokine production in macrophages. The patent, titled "Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages," discloses a highly effective formulation using active components derived from natural products. The composition utilizes a culture obtained from microorganisms belonging to a specific genus as its active component. This innovative approach aims to activate macrophage phagocytosis, particularly targeting cancer cells or cells damaged by anticancer drugs.
Career Highlights
Yasuhiro Nikawa is associated with Aureo Co., Ltd., where he continues to develop and refine his innovative compositions. His work is characterized by a commitment to advancing medical science and improving therapeutic options for patients.
Collaborations
Yasuhiro collaborates with Yukiko Moriya, contributing to the research and development of macrophage-targeting therapies. Their partnership exemplifies the collaborative spirit in scientific research, driving innovation forward.
Conclusion
Yasuhiro Nikawa's contributions to macrophage phagocytosis represent a significant advancement in immunological research. His innovative compositions hold promise for enhancing cancer treatment and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile